[Dysarthria during irinotecan administration].
Ceccaldi
B
B
Kara
F
F
Mommeja-Marin
H
H
Bègue
M
M
Saint Blancard
P
P
Le Marec
E
E
Hauteville
D
D
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004401:Dysarthria / Q000139:chemically induced* / Q000175:diagnosis; D016889:Endometrial Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008279:Magnetic Resonance Imaging
D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin